Precision Medicine Redefines Adjuvant Care in Endometrial Cancer: The PORTEC-4a Trial
Highlights
Individualized adjuvant treatment based on molecular risk profiling was shown to be non-inferior to standard vaginal brachytherapy (VBT) for women with high-intermediate risk (HIR) endometrial cancer. The study successfully spared 46 percent of patients with a favourable molecular profile from any adjuvant treatment, significantly reducing overtreatment without compromising oncological safety. Furthermore, the trial addressed potential undertreatment by intensifying therapy to pelvic radiotherapy for those with unfavourable profiles, while maintaining a low incidence of high-grade toxicities across all cohorts.
